---
title: "Dulaglutide"
canonical_url: https://peptidelibrary.app/library/dulaglutide
description: "FDA-approved once-weekly GLP-1 Fc-fusion peptide (Trulicity) for type 2 diabetes and CV risk reduction in eligible T2D populations."
updated: 2026-11-07
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Dulaglutide

Dulaglutide (also called Trulicity or LY2189265) is an FDA-approved weekly GLP-1 agonist. Dulaglutide is a fusion protein in which two modified human GLP-1 analog sequences are joined by a peptide linker to the Fc fragment of a human IgG4 antibody.

FDA-approved once-weekly GLP-1 Fc-fusion peptide (Trulicity) for type 2 diabetes and CV risk reduction in eligible T2D populations.

Also known as: Trulicity, LY2189265.

Categories: Fat Loss, GLP-1/Metabolic.

## Classification

- Type: FDA-approved weekly GLP-1 agonist
- Mechanism class: GLP-1 Agonist
- Development stage: Approved product
- Regulatory class: FDA-approved medicine

## Mechanism

Dulaglutide is a fusion protein in which two modified human GLP-1 analog sequences are joined by a peptide linker to the Fc fragment of a human IgG4 antibody. Substitutions in the GLP-1 portion confer resistance to dipeptidyl peptidase-4, while the Fc domain both increases hydrodynamic size beyond the renal filtration threshold and engages the neonatal Fc receptor recycling pathway. The combination extends half-life to around five days, supporting weekly dosing. Receptor activation itself is conventional GLP-1 pharmacology: glucose-dependent insulin secretion, suppression of inappropriate glucagon release, slowed gastric emptying, and reduced appetite through hypothalamic and brainstem circuits.

Targets: GLP-1 receptor.

Origin: Recombinant GLP-1–Fc fusion (Lilly).

## Properties

- Molecular weight: ~63 kDa (Fc fusion)
- CAS number: 923950-08-7
- Half-life: ~5 days
- Studied routes: Subcutaneous

## Evidence

- Evidence level: FDA Approved
- Highest documented: Regulatory review (FDA label)
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. TRULICITY (dulaglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with type 2 diabetes mellitus. Glycemic control [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309)
2. TRULICITY (dulaglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Children aged 10 years and older with type 2 diabetes mellitus. Glycemic control [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309)
3. TRULICITY (dulaglutide) injection — FDA prescribing information, DailyMed. Regulatory label (FDA), human. Population: Adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Lower risk of major adverse cardiovascular events [Source](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309)

## Safety

Side effects: GI class effects; Injection-site reactions.

Risks: MTC/MEN2 boxed warning.

Human safety basis: FDA prescribing information

## Regulatory status

Dulaglutide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.

- FDA status: Approved
- WADA status: Permitted
- Availability: Prescription-Only

## Frequently asked questions

### What is Dulaglutide?

FDA-approved once-weekly GLP-1 Fc-fusion peptide (Trulicity) for type 2 diabetes and CV risk reduction in eligible T2D populations.

### How does Dulaglutide work?

Dulaglutide is a fusion protein in which two modified human GLP-1 analog sequences are joined by a peptide linker to the Fc fragment of a human IgG4 antibody. Substitutions in the GLP-1 portion confer resistance to dipeptidyl peptidase-4, while the Fc domain both increases hydrodynamic size beyond the renal filtration threshold and engages the neonatal Fc receptor recycling pathway.

### Is Dulaglutide FDA approved?

Yes. Dulaglutide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.

### What is the half-life of Dulaglutide?

Reported half-life for Dulaglutide is ~5 days. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Dulaglutide banned in sport?

Dulaglutide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.

### What peptides are similar to Dulaglutide?

Compounds most often compared with Dulaglutide include Semaglutide, Tirzepatide, Retatrutide and Liraglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [Trulicity label](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125469s046lbl.pdf)
- [Comparative effectiveness of semaglutide versus liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis — Front Pharmacol, 2025](https://pubmed.ncbi.nlm.nih.gov/40444045/)
- [Mazdutide Versus Dulaglutide for Weight Loss and Diabetes Management: Meta-Analysis of Randomized Clinical Trials — Am J Ther, 2024](https://pubmed.ncbi.nlm.nih.gov/39292847/)
- [Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes — Nature, 2026](https://pubmed.ncbi.nlm.nih.gov/41407860/)
- [Comparison of Dose Escalation Versus Switching to Tirzepatide Among People With Type 2 Diabetes Inadequately Controlled on Lower Doses of Dulaglutide : A Randomized Clinical Trial — Ann Intern Med, 2025](https://pubmed.ncbi.nlm.nih.gov/40183678/)
- [Effect of ketogenic diet plus dulaglutide on glucose and lipid metabolism in diabetes mellitus — Pak J Pharm Sci, 2025](https://pubmed.ncbi.nlm.nih.gov/41241797/)
